Ultilap (Ketorolac Trometamol) is a high-strength analgesic agent generally reserved for the short-term management of acute, severe symptomatic episodes where significant symptomatic assistance is required. The medication is commonly used to help with moderately severe pain, most often after surgery.

This medicine is applied across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort and inflammatory or irritative states. It is relevant for easing symptoms associated with post-surgical recovery, acute trauma, and episodes of intense musculoskeletal pain. The general benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load. It is commonly used when symptoms intensify and supportive relief is needed in settings like emergency departments and acute care.

“The therapeutic intent is to provide supportive relief during phases of increased distress or discomfort.”

Quick Fact: Relief for Acute, Moderately Severe Pain
The medicine is relevant for managing symptoms that interfere with daily comfort, typically in situations involving discomfort associated with acute or episodic changes.

Regulatory References

1. NIH MedlinePlus overview of Ketorolac

Ultilap (Ketorolac Trometamol) is authorized for use only in adult patients for the short-term management of moderately severe acute pain. Use is contraindicated and explicitly prohibited in several populations due to the risk of serious adverse events. Patients must not use this medicine if they have an active or history of peptic ulcer disease or GI bleeding.

It is also contraindicated for individuals with advanced renal impairment or severe hepatic failure, or those with a high risk of bleeding, such as suspected cerebrovascular bleeding. The medicine is contraindicated in patients who have experienced allergic manifestations to aspirin or other NSAIDs, and those concurrently receiving aspirin or any other NSAID.

Regulatory documents state that use is contraindicated during the third trimester of pregnancy, labor, and while breastfeeding. Safety and efficacy are not established for children under the age of 16, and use in this age group is not recommended.

Special restrictions apply to certain eligible populations: Older adults (typically age 65 and older) and patients weighing less than 50 kg are required to receive a reduced maximum daily dose.

Interactions with other medicines and products

Ultilap (Ketorolac Trometamol) has several officially documented interaction patterns based on regulatory labeling. Co-administration is contraindicated with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin, due to the cumulative risk of gastrointestinal bleeding. The medicine Probenecid is also strictly prohibited because it formally causes a significant decrease in Ketorolac clearance, leading to elevated plasma levels.

Pharmacokinetic and Pharmacodynamic Interactions

The interaction profile is defined by Exposure-Altering Pharmacokinetics and Pharmacodynamic Risk Reinforcement. Exposure modification involves Ultilap officially increasing the plasma concentration of co-administered Lithium and Methotrexate by reducing their renal clearance. This reduction in clearance is documented to heighten the toxicity of these medicines. Pharmacodynamic reinforcement is seen with Anticoagulants (like Warfarin) and Antiplatelet agents, where combined use increases the officially documented risk of hemorrhage.

Furthermore, combination with ACE Inhibitors/ARBs or Diuretics may diminish the effect of these blood pressure medicines and increase the risk of renal function deterioration. This risk is specifically cautioned as heightened in elderly and volume-depleted patients in official labeling. The total duration of therapy using all Ultilap formulations (e.g., injection and oral) must not exceed five days. Alcohol use is also noted to increase the risk of gastrointestinal ulcers and bleeding.

Non-Selective Inhibition of Prostanoid Synthesis

The mechanism involves the competitive inhibition of the Cyclooxygenase (COX) enzyme system, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. By blocking the catalytic activity of these enzymes, the drug prevents the conversion of arachidonic acid into prostanoids, including prostaglandins. This action modulates key pathways associated with heightened physiological responses.

---

Dual Peripheral and Central Modulation of Nociceptive Pathways

The resulting reduction in prostaglandin E2 (PGE2) decreases the sensitization of peripheral nociceptors at the injury site. Simultaneously, the mechanism includes an effect within the central nervous system, where it helps reduce the central sensitization of nociceptive signals in the spinal cord. This mechanism engages pathways that influence overactive or dysregulated nociceptive processes, leading to a predictable physiological alteration of nociceptive signal transmission.

---

Mechanism-Linked Effect on Hemostasis

The drug’s non-selective binding to COX-1 carries the predictable physiological consequence of reducing the synthesis of Thromboxane A2 (TXA2) in platelets. This effect reversibly impairs the normal function of platelets, directly demonstrating the systemic influence of the enzyme inhibition mechanism on hemostasis.

How to Use Ultilap (Ketorolac Trometamol)

Ultilap is an analgesic primarily designated for short-term management, and its administration is defined by a strict, limited-duration protocol. The medicine is supplied as a solution for injection (intravenous or intramuscular) and as an oral 10 mg tablet, which is used solely for continuation therapy following initial parenteral administration.

---

Administration Protocol and Dosing

The official use of the medicine begins with parenteral administration, often initiated in a hospital setting. For non-elderly adults weighing over 50 kg, the usual multiple-dose regimen is 30 mg given every 6 hours, with a maximum daily dose of 120 mg for the injectable form. The oral tablet is used to continue the therapy, typically starting with a single 20 mg dose, followed by 10 mg every 4 to 6 hours, with the oral maximum restricted to 40 mg per day.

---

Total Duration and Special Populations

A crucial constraint is that the total combined treatment course—including all forms of Ultilap—must not exceed 5 days in duration. For patients 65 years or older, those weighing less than 50 kg, or those with elevated serum creatinine, a reduced dosing schedule is required: the parenteral dose is 15 mg every 6 hours, and the total maximum daily dose is restricted to 60 mg.

---

Procedural Constraints

Specific procedural instructions govern administration. For the intravenous route, the bolus must be delivered over a minimum of 15 seconds. Furthermore, the protocol requires that any existing volume depletion (hypovolemia) be corrected prior to giving the injection. This two-step, time-constrained administration defines the proper use protocol.

Research Evidence / Overview of Studies for Ultilap

Evidence for Short-Term Management of Acute Post-Surgical Pain

Research has primarily explored Ultilap in studies involving moderately severe physical discomfort following various surgeries. These studies have mainly taken the form of Randomized Controlled Trials (RCTs), comparing Ultilap to placebo or narcotic pain relievers, and focused on adult patients during the time period immediately following their procedure.

Researchers monitored patient-reported outcomes describing perceived discomfort. A key focus was observed in examining how the use of Ultilap related to the amount of narcotic pain relievers (like morphine) that patients needed after their operation. Some studies reported patterns where groups receiving Ultilap recorded less total narcotic use compared to groups receiving placebo. This evidence contributes to understanding symptom patterns, but the data collected usually covers only a very short duration.

---

Evidence for Short-Term Management of Acute Non-Surgical Pain

Ultilap was studied in patients with acute, disruptive episodes of pain that do not stem from surgery, such as discomfort linked to trauma or acute dental issues. Studies exploring short-term symptom changes in these areas often involved single doses and were conducted during periods of increased symptom activity.

In these research scenarios, outcomes related to physical discomfort that studies monitored were the time to onset of relief and the total reported reduction in symptom intensity over a few hours. The data for this indication are still emerging, and findings can be variable depending on the specific cause of the pain. The research provides insight into short-term changes, but there is limited information for outcomes over extended periods.

---

Duration of Evidence and Follow-Up Periods

The research base mainly involves short-term observation over periods of only a few days. This focus is consistent with the short duration of use examined in the trials. This means that long-term effects are not fully established in the available controlled research. The current evidence contributes to the broader evidence landscape of short-term relief, but research does not determine whether an individual will experience sustained changes after the medicine is stopped.

---

Evidence in Specific Patient Groups

Studies exploring the use of Ultilap in older adults have been limited, and the results apply only to the specific populations studied in those trials. For pediatric patients (children and adolescents), evidence quality varies across studies. This means that for pediatric pain management, certainty remains low, and there is a recognized data gap regarding safe and effective dosing compared to the extensive evidence available for adults.

---

The Research Landscape: Consistency, Limitations, and Gaps

The research base is considered to have a substantial body of evidence primarily due to the number of Randomized Controlled Trials applied in studies examining post-surgical pain. However, a key limitation is that follow-up durations were limited across almost all major trials. Furthermore, studies explored outcomes related to physical discomfort, but the evidence for secondary measures (such as returning to typical activity levels) appears to vary, and subgroup findings are uncertain across different patient types. Research is ongoing.

Key Studies & References

1. KETOROLAC TROMETHAMINE - ketorolac tromethamine injection (FDA Label/DailyMed)
2. Ketorolac Injection and Tablets (MedlinePlus Drug Information)

Common questions about Ultilap (FAQ)

---

Q: Is Ultilap the same type of medicine as [similar drug name]?

Official product information classifies Ultilap (Ketorolac Trometamol) as a potent Nonsteroidal Anti-Inflammatory Drug (NSAID). Its structure is a synthetic pyrrolo-pyrrole derivative. The drug's classification defines the general family of medicines it belongs to.

---

Q: How quickly should I expect Ultilap to start working?

Regulatory documents indicate that after an injection (IV or IM), the pain-relieving effect begins in approximately mathbf30 minutes, reaching its maximum strength within one to two hours. When the oral tablet is taken, peak absorption is generally reached within an hour.

---

Q: Are there any common foods or drinks to avoid while using Ultilap?

Official warnings state that alcohol use is noted to increase the risk of gastrointestinal ulcers and bleeding. Regarding food, official product information notes that taking the oral tablet with food or a snack can be associated with lessened stomach upset. While a high-fat meal can slow how quickly the medicine is absorbed, regulatory data indicates it does not significantly change the overall amount of the drug in the body.

---

Q: Is it possible to feel tired or dizzy when starting Ultilap?

Yes, regulatory safety documents list dizziness and drowsiness among the commonly reported adverse reactions in clinical data. Caution is advised regarding tasks requiring mental alertness, such as driving.

---

Q: Does Ultilap interact with common pain relievers like ibuprofen or aspirin?

Regulatory product information specifies that co-administration is contraindicated (strictly prohibited) with aspirin and other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. This is due to a heightened and cumulative risk of serious side effects, particularly gastrointestinal bleeding.

---

Q: Does Ultilap affect blood pressure or heart rate?

Regulatory safety documents note that the medicine can be associated with adverse reactions including edema (fluid retention or swelling) and hypertension (high blood pressure). Official guidance states that blood pressure should be monitored during treatment.

---

Q: Can Ultilap be used by elderly patients?

Yes, but patients mathbf65 years or older are officially recognized as being at a greater risk for serious adverse events, such as GI bleeding. For this reason, official prescribing information requires that this population receive a reduced maximum daily dose.

---

Q: What is the longest period a person usually takes Ultilap?

The maximum total combined treatment course—including all forms of Ultilap (oral and injection)—must not exceed 5 days in duration. Regulatory warnings indicate that the risk of serious adverse events increases after the first five days.

---

Q: Is it normal to have mild headaches when first starting Ultilap?

Headache is reported as a very common adverse reaction, with clinical data showing it occurred in mathbf10% or more of patients. It is listed as one of the most frequent events associated with the use of this medicine.

---

Q: Does Ultilap have a risk of dependence or withdrawal symptoms?

According to the official clinical profile, Ultilap is classified as an NSAID and a non-narcotic agent. Studies confirm it has no significant alteration in opioid-like pharmacodynamics, and the drug does not cause dependency or addiction.

---

Q: Can men and women use Ultilap for the same conditions?

The medicine is authorized for the short-term management of moderately severe acute pain in adult patients generally. Contraindications related to sex are specific to women during the third trimester of pregnancy, labor, and while breastfeeding.

---

Q: What is the difference between Ultilap and its listed 'mechanism of action'?

Ultilap is the brand name for the active drug substance, which is Ketorolac Trometamol. The mechanism of action is the biological process by which the substance works, which is the inhibition of the COX enzyme system to stop the production of pain- and inflammation-causing prostaglandins.

---

Q: Are there any warnings about driving or operating machinery while on Ultilap?

Official warnings advise that caution be exercised regarding tasks that require mental alertness, such as driving or operating heavy machinery, due to possible side effects like dizziness and drowsiness.

---

Q: Can Ultilap cause changes in weight?

Regulatory safety documents list edema (fluid retention or swelling) and unusual weight gain as possible side effects. These effects are associated with the medicine's influence on fluid balance and renal function.

---

Q: Does taking Ultilap with food change how it works?

Official product information notes that taking the oral tablet with food or a snack can be associated with lessened stomach upset. While a high-fat meal can slow how quickly the medicine is absorbed, it does not significantly change the overall amount of the drug in the body.

---

Q: How long does the main effect of one dose of Ultilap last?

The median duration of the pain-relieving effect following an injection is generally reported in regulatory documents to be four to six hours. This is consistent with its authorized use for short-term pain management.

---

Q: Is Ultilap a controlled substance?

No, Ultilap (Ketorolac Trometamol) is a prescription-only medicine but is not classified as a controlled substance by regulatory bodies like the Drug Enforcement Administration (DEA) in the US.

---

Q: Does Ultilap interact with vitamins or herbal supplements?

Regulatory documents list numerous interactions with specific prescription medicines. Potential interactions with other agents, including vitamins and herbal supplements, mean that professional assessment is necessary to confirm eligibility.

---

Q: What if I'm already taking multiple medicines—is Ultilap still an option?

Regulatory information lists numerous specific medicines that are either contraindicated (strictly prohibited) or require extreme caution if taken with Ultilap. The presence of numerous documented interactions means that eligibility for Ultilap depends on a professional assessment of the complete list of medications being used.

---

Q: How does Ultilap compare to the placebo group in research studies?

Randomized Controlled Trials (RCTs) reported patterns where patient groups receiving Ultilap recorded less total narcotic pain reliever use compared to groups receiving a placebo. This evidence contributes to understanding symptom patterns over a short duration.

---

Q: Are there specific criteria for who is eligible to use Ultilap?

Yes. The medicine is authorized only for adult patients for the short-term management of moderately severe acute pain that requires opioid-level analgesia. It is generally restricted to continuation therapy following initial injection, and many other health conditions are absolute contraindications.

---

Q: Does Ultilap cause stomach upset or nausea?

Yes. According to clinical data, nausea, vomiting, and dyspepsia (a term for indigestion or stomach upset) are listed among the most commonly reported adverse reactions associated with the medicine.

---

Q: Does Ultilap have a known interaction with alcohol?

Yes. Regulatory documents explicitly state that alcohol use is noted to increase the officially documented risk of gastrointestinal ulcers and bleeding. This is a safety concern highlighted in the official product information.

---

Q: What are the most serious, but rare, side effects of Ultilap?

The most serious risks are the Boxed Warnings for Gastrointestinal (GI) bleeding/perforation and Cardiovascular (CV) thrombotic events (like heart attack or stroke). Regulatory safety lists also note rare, severe skin reactions, such as Stevens-Johnson syndrome.

---

Q: Is the research evidence for Ultilap considered strong or limited?

The research base is considered to have a substantial body of evidence primarily in post-surgical pain based on numerous Randomized Controlled Trials. However, official documents note a key limitation: follow-up durations were limited (short-term only), meaning long-term effects are not fully established in controlled research.

---

Q: Can Ultilap be used in pediatric (child) patients?

Regulatory product information states that safety and efficacy are not established for children under the age of 16 in standard labeling. Due to this recognized data gap, use in this age group is not recommended.

How to Store and Dispose of Ultilap

Ultilap (Ketorolac Tromethamine) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

---

Storage Conditions and Requirements

The medication is required to be stored at a Controlled Room Temperature, defined as a range between 15°C and 30°C (59°F and 86°F). The container must be kept tightly closed and should be light-resistant, as defined by dispensing regulations. Storage in areas with excess heat or moisture, such as a bathroom, is prohibited.

Child Safety: A mandatory requirement is to KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

---

Disposal Instructions

Official disposal protocols prioritize using a community-based drug take-back program. If this is not available, the alternative is to follow the household disposal procedure: mix the medicine with an undesirable substance (like coffee grounds or dirt) and place it in a sealed container before discarding it in the household trash. The medication must not be flushed down a toilet or sink.